Suche Bilder Maps Play YouTube News Gmail Drive Mehr »
Erweiterte Patentsuche | Webprotokoll | Anmelden

Patente

VeröffentlichungsnummerUS4081372 A
PublikationstypErteilung
Anmeldenummer05/638,729
Veröffentlichungsdatum28. März 1978
Eingetragen8. Dez. 1975
Prioritätsdatum8. Dez. 1975
Veröffentlichungsnummer05638729, 638729, US 4081372 A, US 4081372A, US-A-4081372, US4081372 A, US4081372A
ErfinderCurtis Lyman Atkin, Robert Longfield Stephen
Ursprünglich BevollmächtigterUniversity Of Utah
Externe Links: USPTO, USPTO-Zuordnung, Espacenet
Leakage indicator for recirculating peritoneal dialysis system
US 4081372 A
Zusammenfassung
Hemoglobin or hemolysate is used as an indicator for leakage detection in the dialysis membrane interface separating the sterile from the nonsterile circuitry in a recirculating peritoneal dialysis system. The indicator is dissolved in the steril dialysis fluid and is retained within the sterile circuit unless leakage occurs in the membrane. Upon rupture or other leakage in the membrane, fluid turbulance and pressure gradient cause crossflow between the sterile and nonsterile circuitry, endangering the patient with infection, peritonitis and endotoxin shock. Such crossflow is detected by the concurrent coloration caused by the mixing of hemoglobin indicator in the nosterile dialysis fluid.
Bilder(1)
Previous page
Next page
Ansprüche
We claim:
1. An apparatus for the detection of leakage of a first, substantially colorless sterile solution from a closed system in parenteral administrations, said leakage to occur through an interface means separating said first solution from a second solution wherein the colorless state of the first solution makes visual detection of leakage or flow difficult or impossible, comprising:
a. a source of hemolysate or other hemoglobin based indicator having strong coloration characteristics upon dilution into larger volumes of colorless solution, and
b. means for introducing said hemolysate into the first solution in sufficient quantity to develop detectable color intensity upon leakage into said second solution.
2. An apparatus as defined in claim 1, further comprising a means for in-process observation of coloration changes within said second solution.
3. An apparatus as defined in claim 1, further comprising a means for warning of the presence of hemolysate coloration of said second solution.
4. An apparatus as defined in claim 2, further comprising a means for warning of hemolysate coloration of said second solution.
5. In a recirculating peritoneal dialysis system having one or more sterile fluid circuits, one or more nonsterile fluid circuits and appropriate interfaces therebetween, an apparatus for the detection of dialysis membrane leakage, comprising:
a. a source of hemolysate or other hemoglobin based leakage indicator having strong coloration characteristics, and
b. means for introducing said hemolysate into a sterile circuit for marking sterile dialysis fluid.
6. An apparatus as defined in claim 5, further comprising a means for observing coloration of circulating nonsterile dialysis fluid immediately following exposure to said dialysis membrane.
7. An apparatus as defined in claim 5, further comprising a means for detecting and/or warning of hemolysate coloration within said nonsterile dialysis circuit.
8. An apparatus as defined in claim 6, wherein the observing means is a cuvet coupled into the nonsterile dialysis circuit to provide a longitudinal view down the length of the cuvet fluid path for increased sensitivity in detection of coloration.
9. An apparatus as defined in claim 6, wherein the observing means is an observation cell coupled into the nonsterile dialysis circuit to enable direct viewing of the circulating nonsterile fluid.
10. An apparatus as defined in claim 6, further comprising a means for warning of the hemolysate coloration within said nonsterile dialysis circuit.
11. An apparatus as defined in claim 7, wherein said detecting means is a photometric monitoring device.
Beschreibung
DETAILED DESCRIPTION

The above and other objects of the present invention are realized in the following specific illustrative embodiment of a typical recirculating peritoneal dialysis system as shown in the FIGURE. The sterile dialysis fluid is introduced into the sterile circuit 2 from a reservoir of such solution 7. An appropriate amount of indicator is concurrently injected into the sterile circuit from a second reservoir 1 in sufficient quantity to give the sterile fluid adequate color intensity for immediate detection upon leakage. Experimentation has shown that 0.1g/dl (0.1% w/v) hemoglobin is sufficient concentration of indicator to give timely notice of membrane leakage. Larger amounts of indicator may be utilized, however, in view of the harmless nature of the hemolysate.

The colored, sterile fluid is then pumped through the sterile circuit from the peritoneal cavity 8 to the dialysis membrane 4 where the well known dialysis function occurs. If the membrane is functioning properly, the large molecular size of hemolgobin precludes its passage into the nonsterile circuit 3 in which a larger volume of nonsterile dialysis fluid is being circulated on the opposite side of the membrane. After dialysis, the sterile fluid is returned to the peritoneal cavity and the recirculation process continued until completion of the treatment.

If, however, a rupture or leakage in the membrane occurs, fluid turbulance and pressure gradient the hemoglobin to pass into the nonsterile system. The diffusion of even minute quantities of hemolysate indicator into the circulating, nonsterile dialysis fluid results in sufficient coloration of the nonsterile fluid to enable visual or photometric detection at the flow cuvet 5 immediately following the membrane dialyzer within the nonsterile circuit. A standard photometric detector 6 may be utilized for automatic and continuous monitoring of the nonsterile fluid. The attachment of visual and/or audio alarming device provides instantaneous warning of membrane leakage.

Although the patient's own whole blood would serve as an ideal indicator, concurrent anemia usually precludes such blood loss. Consequently, an outside source of indicator is preferable. Although cross-matched donor blood would have the appropriate coloration effect, its repeated use as an indicator is unsatisfactory because of risks of immunological sensitization that might well endanger the success of future kidney transplantation or transfusions. Few kidney-failure patients would willingly foreclose such opportunities for future transplantations or transfusions which might be required for survival.

Utilization, however, of only the hemolysate or hemoglobin from donor blood, instead of whole blood, eliminates the immunological problems discussed above. This distinction arises from the fact that hemoglobin, unlike the blood group antigens, is a molecule essentially equivalent within all persons. Therfore, the risks of antibody reactions accompanying administration of common donor blood are not experienced.

The hemolysate indicator is prepared from donor blood by (1) removal of plasma and buffy coat, (2) saline washing, (3) water hemolysis and (4) centrifugal separation of hemolysate from membranous material and residual cells. These procedures are accomplished in sterile fashion and require only slight modification of standard techniques. Tests for effective removal of ABO and other antigens, and tests for sterility and freedom from endotoxin (pyrogen) are all performed by standard techniques. Inactivation of hepatitis virus is achieved by heat treatment in accordance with current practice for some plasma protein fractions, notably albumin. The indicator may be stabilized for long-term storage by treatment with carbon monoxide and/or by freeze drying.

Hemoglobin is the predominant component of hemolysate indicator prepared as described above. Any minor proteins and metabolites from red cell cytoplasma remaining in the indicator are nontoxic and have no demonstrated allergic effects. Unlike the blood group and histocompatibility antigens, these minor constituents are essentially identical in all people. If desired, however, these extraneous materials may be eliminated by standard techniques for purification of hemoglobin.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawing shows a typical peritoneal dialysis system.

BACKGROUND OF THE INVENTION

This invention relates to a system and technique for detection of leakage in a peritoneal dialysis membrane, or in leakage or flow in other closed systems where the colorless state of the body fluid being monitored makes visual detection of leakage or flow difficult or impossible.

Current therapy of patients who have suffered kidney failure consists of kidney transplantation or dialysis treatment. Although hemodialysis is at present the best developed and most widely used dialysis technique, it is impractical for patients with clotting or blood-access problems, notably diabetics. Peritoneal dialysis has been demonstrated as a successful alternative treatment for such persons. A severe problem, however, with the recirculating peritoneal dialysis system is the need for rapid detection of the occasional leaks in the dialysis membrane. Statistically, each dialysis treatment has approximately a 5% chance of membrane leakage. Early detection of such leakage is critical because introduction of nonsterile fluid through the membrane into the peritoneal cavity endangers the patient with peritonitis, infection, and endotoxin shock.

Current methods of protecting the patient from such risks are seriously inadequate. Prior to the dialysis, the membrane is subjected to fluid pressure testing to ensure proper working order. Once the treatment is begun, however, membrane failure can be detected only by falling fluid pressure on the sterile side, increasing fluid volume on the nonsterile side, or by appearance of cloudiness in the nonsterile side. The primary weakness of such methods is that only massive leaks can be detected, and the patient may already be endangered before corrective action can begin.

SUMMARY OF THE INVENTION

The present invention utilizes the intense color of hemoglobin to permit immediate detection of membrane leakage from the sterile circuit of the recirculating peritoneal dialysis system. The coloration of the sterile dialysis fluid is accomplished by the addition of hemoglobin or hemolysate indicator. As this colored fluid is pumped through the sterile circuit from the patient to the dialysis membrane and back to the patient in a recirculating manner, the indicator molecules are retained within the sterile system. The nonsterile fluid passing in contact with the other side of the dialysis membrane remains colorless as long as the membrane is functioning properly.

Upon rupture of the membrane during the dialysis process, fluid turbulance causes the hemolysate molecules to pass through the resulting aperture, giving a measureable change of color to the otherwise clear, nonsterile fluid. This color change is detected as the nonsterile fluid passes through an obseravation cell or cuvet within the nonsterile circuit of the dialysis system.

It is an object of the present invention to provide a system and method for detection of leakage or flow in closed parenteral or body fluid systems where the sterile fluid leakage or flow is not easily detectable due to its near colorless state.

It is further an object of this invention to provide a system and method to give immediate warning of rupture or leakage in the dialysis membrane during recirculating peritoneal dialysis treatment.

It is also an object of the present invention to provide a system and method for leakage detection in which the color indicator is of sufficiently large molecular weight that diffusion of the indicator through the dialysis membrane occurs only where an abnormal aperture appears and without interfering with the dialysis process.

It is a further object of the present invention to provide a macromolecular marker with such strong light-absorbing properties, or color, that it be detectable in solution at extreme dilutions by visual or photometric means.

It is another object of the present invention to provide such a system and method in which the indicator is sterile, chemically noninterfering, organically biodegradable, intrinsically nonantigenic, and free of antibodies and of plasma and blood cellular membrane antigens such that no ill effects result from residual indicator remaining within the patient after peritoneal dialysis or other parenteral use.

A further object of the present invention is to provide such a system in which surveillance of dialysis membrane performance may be continued throughout the dialysis administration without interruption, risk or discomfort to the patient.

This invention was developed with the support of a research grant from Hematology, National Institute of Arthritis, Metabolism and Digestive Diseases, National Institute of Health, Department of Health, Education and Welfare, United States Government, under Grant No. AM-04489-16.

Patentzitate
Zitiertes PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US3519572 *3. Okt. 19667. Juli 1970Chas. Pfizer & Co. Inc.Blood control
US3802562 *7. Apr. 19729. Apr. 1974A Su KhaltlinDistributor of dialyzing solution
US3873467 *1. Febr. 197425. März 1975United Medical Laboratories, Inc.Hematologic reference control
US3900396 *22. März 197419. Aug. 1975Baxter Laboratories, Inc.Blood leak detector
Nichtpatentzitate
Referenz
1Shinaberger et al., "Increasing Efficiency--Recirculation Dialysis," from vol. XI, Trans. Amer. Soc. Artif. Int. Organs, 1965 pp. 76-82.
Referenziert von
Zitiert von PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US4190047 *26. Aug. 197726. Febr. 1980University Of UtahMethod and apparatus for peritoneal dialysis
US4253456 *21. Aug. 19783. März 1981Dr. Eduard Fresenius Chemisch-Pharmazeutisch Industrie Kg, Apparatebau KgArtificial endocrinal gland
US4265760 *26. Febr. 19795. Mai 1981Becton Dickinson & CompanyDevice for dilution and delivery of in vivo chemicals
US4276175 *19. Juli 197930. Juni 1981Bower; John D.Regeneratable peritoneal dialysis bag
US4329986 *14. Juni 197918. Mai 1982Biomedics, Inc.Treatment of an extracorporeal stream of blood with a dialyzable chemotherapeutic and a fluorescable tracer
US4338190 *8. Febr. 19776. Juli 1982A. T. Ramot Plastics Ltd.Peritoneal artificial kidney
US4353368 *19. Aug. 198012. Okt. 1982Ceske Vysoke Uceni TechnickeDevice for hemodialysis
US4403992 *1. Okt. 198113. Sept. 1983Sis-Ter S.P.A.Continuous peritoneal dialysis bag device
US4468329 *4. Juni 198128. Aug. 1984Gambro Lundia AbHemofiltration system and safety system therefor
US4618343 *12. Sept. 198421. Okt. 1986Fresenius AgApparatus for peritoneal dialysis
US4765907 *18. Okt. 198423. Aug. 1988Research Development Systems, Inc.Wearable, continuously internally operable and externally regenerable dialysis device
US5510716 *1. Nov. 199423. Apr. 1996Cobe Laboratories, Inc.Differential conductivity recirculation monitor
US5510717 *31. Mai 199523. Apr. 1996Cobe Laboratories, Inc.Differential conductivity recirculation monitor
US5570026 *31. Mai 199529. Okt. 1996Cobe Laboratories, Inc.Altered fluid conductivity monitor
US5631552 *7. Juni 199520. Mai 1997Cobe Laboratories, Inc.Hemodynamic monitor for detecting air bubbles
US5711883 *27. Sept. 199527. Jan. 1998Fresenius Usa, Inc.Method for testing dialyzer integrity prior to use
US5813408 *15. Sept. 199529. Sept. 1998Boston Scientific Technology, Inc.Surgical drape
US5900726 *16. Juni 19974. Mai 1999Cobe Laboratories, Inc.Differential conductivity hemodynamic monitor
US6075367 *23. Dez. 199813. Juni 2000Gambro, Inc.Differential conductivity hemodynamic monitor
US618938812. Nov. 199720. Febr. 2001Gambro, Inc.Access flow monitoring using reversal of normal blood flow
US62105912. Juli 19993. Apr. 2001Transonic Systems, Inc.Method to measure blood flow rate in hemodialysis shunts
US626654628. Mai 199824. Juli 2001In-Line Diagnostics CorporationSystem for noninvasive hematocrit monitoring
US64523712. Mai 200017. Sept. 2002Gambro, Inc.Differential conductivity hemodynamic monitor
US658265628. März 200024. Juni 2003In-Line Diagnostics CorporationSystem and method for noninvasive hemodynamic measurements in hemodialysis shunts
US661421210. Sept. 20022. Sept. 2003Gambro, Inc.Differential conductivity hemodynamic monitor
US668112813. Juni 200120. Jan. 2004Hema Metrics, Inc.System for noninvasive hematocrit monitoring
US668751922. Jan. 20013. Febr. 2004Hema Metrics, Inc.System and method for measuring blood urea nitrogen, blood osmolarity, plasma free hemoglobin and tissue water content
US672507229. Dez. 200020. Apr. 2004Hema Metrics, Inc.Sensor for transcutaneous measurement of vascular access blood flow
US672664722. Okt. 199927. Apr. 2004Gambro AbMethod and device for measuring access flow
US674640729. Dez. 20008. Juni 2004Hema Metrics, Inc.Method of measuring transcutaneous access blood flow
US680454319. März 200212. Okt. 2004Hema Metrics, Inc.Sensor for transcutaneous measurement of vascular access blood flow
US686873919. Okt. 199922. März 2005Transonic Systems, Inc.Method and apparatus to measure blood flow by an introduced volume change
US691291729. Juli 20035. Juli 2005Gambro, Inc.Differential fluid parameter determination
US69378829. Dez. 200330. Aug. 2005Hema Metrics, Inc.Sensor for transcutaneous measurement of vascular access blood flow
US69879939. Dez. 200317. Jan. 2006Hema Metrics, Inc.Sensor for transcutaneous measurement of vascular access blood flow
US712115018. März 200517. Okt. 2006Transonic Systems, Inc.Method and apparatus to determine an initial flow rate in a conduit
US717257028. Jan. 20046. Febr. 2007Gambro Lundia AbApparatus and method for monitoring a vascular access of a patient subjected to an extracorporeal blood treatment
US729728018. Juni 200420. Nov. 2007Transonic Systems, Inc.Method and apparatus to measure blood flow in hemodialysis shunts
US747337113. Apr. 20056. Jan. 2009Transonic Systems, Inc.Measurement of a blood flow rate in hemodialysis shunts
US750095827. Febr. 200410. März 2009Gambro Lundia AbSwitch valve for an extracorporeal blood circuit and circuit including such a switch valve
US774918420. Dez. 20066. Juli 2010Gambro Lundia AbApparatus and method of monitoring a vascular access of a patient subjected to an extracorporeal blood treatment
US779441918. Mai 200514. Sept. 2010Gambro Lundia AbApparatus for controlling blood flow in an extracorporeal circuit
US781585218. Nov. 200419. Okt. 2010Gambro Lundia AbMethod, apparatus and software program for measurement of a parameter relating to a heart-lung system of a mammal
US783691410. Dez. 200423. Nov. 2010Gambro Lundia AbSwitching device and apparatus for controlling flow of a fluid
US786721417. Juli 200311. Jan. 2011Baxter Healthcare S.A.Systems and methods for performing peritoneal dialysis
US78968316. März 20091. März 2011Gambro Lundia AbMethod and apparatus for calculating fluid flow rate
US792268617. Juli 200312. Apr. 2011Baxter Healthcare S.A.Systems and methods for performing peritoneal dialysis
US792291129. Mai 200912. Apr. 2011Baxter Healthcare S.A.Systems and methods for peritoneal dialysis
US795529127. Aug. 20097. Juni 2011Gambro Lundia AbMethod and apparatus for detecting access recirculation
US835711318. Sept. 200922. Jan. 2013Baxter International Inc.Systems and methods for performing peritoneal dialysis
US836666711. Febr. 20105. Febr. 2013Baxter International Inc.Flow pulsatility dampening devices
EP0042939A1 *8. Mai 19816. Jan. 1982Gambro Lundia ABHemofiltration system
EP0087171A1 *8. Mai 198131. Aug. 1983Gambro Lundia ABSafety system for control of a filter
EP2338543A1 *16. Juli 200329. Juni 2011Baxter International Inc.Systems for performing peritoneal dialysis
WO1985004341A1 *26. März 198510. Okt. 1985Research Development Systems, Inc.Internal dialyzer with wearable external regeneration
WO2004008826A2 *16. Juli 200329. Jan. 2004Baxter International Inc.Systems and methods for performing peritoneal dialysis
Klassifizierungen
US-Klassifikation210/94, 210/321.6, 210/96.2, 604/29
Internationale KlassifikationA61M1/28, A61M1/16
UnternehmensklassifikationA61M2205/705, A61M1/1692, A61M1/28, A61M2001/281, A61M1/1696
Europäische KlassifikationA61M1/28